GSA Capital Partners LLP Has $2.58 Million Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

GSA Capital Partners LLP decreased its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 33.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 153,239 shares of the company's stock after selling 78,496 shares during the quarter. GSA Capital Partners LLP owned approximately 0.07% of Cellebrite DI worth $2,581,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Janney Montgomery Scott LLC lifted its holdings in shares of Cellebrite DI by 240.1% during the first quarter. Janney Montgomery Scott LLC now owns 45,300 shares of the company's stock worth $502,000 after buying an additional 31,981 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Cellebrite DI by 34.8% in the first quarter. SG Americas Securities LLC now owns 51,881 shares of the company's stock worth $575,000 after purchasing an additional 13,392 shares during the period. Sei Investments Co. increased its position in shares of Cellebrite DI by 44.7% in the first quarter. Sei Investments Co. now owns 121,166 shares of the company's stock worth $1,343,000 after purchasing an additional 37,408 shares during the period. Inspire Investing LLC bought a new position in shares of Cellebrite DI in the first quarter worth $862,000. Finally, Russell Investments Group Ltd. increased its position in shares of Cellebrite DI by 92.5% in the first quarter. Russell Investments Group Ltd. now owns 16,649 shares of the company's stock worth $188,000 after purchasing an additional 8,001 shares during the period. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock traded up $0.21 during midday trading on Tuesday, reaching $18.58. The company had a trading volume of 1,126,610 shares, compared to its average volume of 1,154,958. The stock has a fifty day moving average price of $17.64 and a 200 day moving average price of $14.39. The firm has a market cap of $3.83 billion, a PE ratio of -11.85, a P/E/G ratio of 2.52 and a beta of 1.50. Cellebrite DI Ltd. has a fifty-two week low of $7.32 and a fifty-two week high of $21.00.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.05. The company had revenue of $106.90 million for the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The firm's quarterly revenue was up 27.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.09 earnings per share. As a group, sell-side analysts forecast that Cellebrite DI Ltd. will post 0.31 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CLBT. TD Cowen raised their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. Lake Street Capital lifted their target price on Cellebrite DI from $13.50 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Deutsche Bank Aktiengesellschaft lifted their target price on Cellebrite DI from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Bank of America lifted their target price on Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Finally, Needham & Company LLC lifted their target price on Cellebrite DI from $17.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI has a consensus rating of "Buy" and a consensus target price of $20.29.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.